谁想换药？评估患者对新型抗逆转录病毒疗法的兴趣。
Who Wants to Switch? Gauging Patient Interest in Novel Antiretroviral Therapies.
作者信息
Derrick Caroline B, Ostermann Jan, Weissman Sharon B, Hobbie Amy, Alshareef Noor, Weinhold Andrew, Yelverton Valerie, Thielman Nathan M
机构信息
Department of Medicine, School of Medicine, University of South Carolina, Columbia, South Carolina.
Department of Health Services Policy and Management, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina.
出版信息
Open Forum Infect Dis. 2018 Oct 22;5(10):ofy247. doi: 10.1093/ofid/ofy247. eCollection 2018 Oct.
Abstract
Study participants were asked about their interest in switching to novel drug delivery systems that reduce the dosing frequency of antiretroviral regimens. Across a diverse, treatment-experienced cohort, we describe greatest interest in switching to an oral regimen taken once weekly, followed by injections taken every other month and twice-annual implants.
摘要
研究参与者被问及他们对改用新型药物递送系统的兴趣，这些系统可减少抗逆转录病毒疗法的给药频率。在一个多样化的、有治疗经验的队列中，我们发现对改用每周服用一次的口服疗法兴趣最大，其次是每两个月注射一次和每年植入两次。
相似文献
1
Who Wants to Switch? Gauging Patient Interest in Novel Antiretroviral Therapies.谁想换药？评估患者对新型抗逆转录病毒疗法的兴趣。
Open Forum Infect Dis. 2018 Oct 22;5(10):ofy247. doi: 10.1093/ofid/ofy247. eCollection 2018 Oct.
2
Comparison of Antiretroviral Regimens: Adverse Effects and Tolerability Failure that Cause Regimen Switching.抗逆转录病毒治疗方案的比较：导致方案转换的不良反应和耐受性失败
Infect Chemother. 2015 Dec;47(4):231-8. doi: 10.3947/ic.2015.47.4.231. Epub 2015 Dec 30.
3
Antiretroviral treatment in pediatric HIV infection in the United States: from clinical trials to clinical practice.美国儿童HIV感染的抗逆转录病毒治疗：从临床试验到临床实践
JAMA. 2005 May 11;293(18):2213-20. doi: 10.1001/jama.293.18.2213.
4
A Mixed Methods Approach to Understanding Antiretroviral Treatment Preferences: What Do Patients Really Want?一种理解抗逆转录病毒治疗偏好的混合方法：患者真正想要的是什么？
AIDS Patient Care STDS. 2018 Sep;32(9):340-348. doi: 10.1089/apc.2018.0099.
5
Simplification from twice-daily to once-daily darunavir/ritonavir in a randomized trial among HIV-infected persons with HIV-1 RNA suppression on antiretroviral therapy.在一项针对接受抗逆转录病毒治疗且HIV-1 RNA得到抑制的HIV感染者的随机试验中，将达芦那韦/利托那韦从每日两次简化为每日一次。
Antivir Ther. 2015;20(8):849-54. doi: 10.3851/IMP2962. Epub 2015 Apr 17.
6
[Longitudinal study on adherence, treatment satisfaction, and effectiveness of once-daily versus twice-daily antiretroviral therapy in a Spanish cohort of HIV-infected patients (CUVA study)].[西班牙一组HIV感染患者中一日一次与一日两次抗逆转录病毒疗法的依从性、治疗满意度及有效性的纵向研究（CUVA研究）]
Enferm Infecc Microbiol Clin. 2008 Mar;26(3):127-34. doi: 10.1157/13116748.
7
Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz.在一项为期48周的随机研究中，关于齐多夫定/拉米夫定继续用药或换用替诺福韦酯/恩曲他滨（均联合依非韦伦）的抗逆转录病毒疗法、治疗依从性和生活质量的相关信念。
AIDS Care. 2011 Jun;23(6):705-13. doi: 10.1080/09540121.2010.534433.
8
Successive switching of antiretroviral therapy is associated with high psychological and physical burden.抗逆转录病毒疗法的连续换药会带来很高的心理和身体负担。
Int J STD AIDS. 2007 Oct;18(10):700-4. doi: 10.1258/095646207782193821.
9
Healthcare resource utilization and costs in patients with HIV-1 who switched first-line antiretroviral therapy.HIV-1 感染者一线抗逆转录病毒治疗转换后医疗资源利用和成本。
Curr Med Res Opin. 2019 Nov;35(11):1945-1953. doi: 10.1080/03007995.2019.1644850. Epub 2019 Aug 22.
10
Effect of twice-daily nevirapine on adherence in HIV-1-infected patients: a randomized controlled study.每日两次服用奈韦拉平对HIV-1感染患者依从性的影响：一项随机对照研究。
AIDS. 2007 Oct 18;21(16):2217-22. doi: 10.1097/QAD.0b013e3282eff388.
引用本文的文献
1
"Injectable ARVs will give me peace" women's acceptability of injectable antiretroviral therapy in prevention of HIV vertical transmission in Uganda.“注射用抗逆转录病毒药物将给我带来安心”：乌干达女性对注射用抗逆转录病毒疗法预防艾滋病毒垂直传播的可接受性
Sci Rep. 2025 Jul 16;15(1):25818. doi: 10.1038/s41598-025-10686-8.
2
Two phase 1 studies of safety, tolerability, and pharmacokinetics of an EFdA prodrug (BRII-732) in healthy adult participants.关于一种EFdA前药（BRII-732）在健康成年受试者中的安全性、耐受性和药代动力学的两项1期研究。
Antimicrob Agents Chemother. 2025 Jun 4;69(6):e0020025. doi: 10.1128/aac.00200-25. Epub 2025 Apr 22.
3
Ethical issues surrounding the implementation of long-acting injectable antiretroviral therapy in sub-Saharan Africa.撒哈拉以南非洲地区长效注射抗逆转录病毒疗法实施过程中涉及的伦理问题。
Int Health. 2025 Sep 3;17(5):695-700. doi: 10.1093/inthealth/ihaf016.
4
Patient and Physician Preferences for Regimen Attributes for the Treatment of HIV in the United States and Canada.美国和加拿大患者及医生对艾滋病治疗方案属性的偏好
J Pers Med. 2022 Feb 23;12(3):334. doi: 10.3390/jpm12030334.
5
The LAIs Are Coming! Implementation Science Considerations for Long-Acting Injectable Antiretroviral Therapy in the United States: A Scoping Review.长效注射剂即将到来！美国长效注射抗逆转录病毒疗法的实施科学考量：一项范围综述。
AIDS Res Hum Retroviruses. 2021 Feb;37(2):75-88. doi: 10.1089/AID.2020.0126. Epub 2020 Dec 7.
6
Reasons People Living with HIV Might Prefer Oral Daily Antiretroviral Therapy, Long-Acting Formulations, or Future HIV Remission Options.人们选择口服每日抗逆转录病毒疗法、长效制剂或未来的艾滋病缓解选择的原因。
AIDS Res Hum Retroviruses. 2020 Dec;36(12):1054-1058. doi: 10.1089/AID.2020.0107. Epub 2020 Sep 14.
7
Qualitative Thematic Analysis of Social Media Data to Assess Perceptions of Route of Administration for Antiretroviral Treatment among People Living with HIV.社交媒体数据的定性主题分析，以评估艾滋病毒感染者对艾滋病抗病毒治疗途径的看法。
Patient. 2020 Aug;13(4):409-422. doi: 10.1007/s40271-020-00417-8.
8
The Dose Response: Perceptions of People Living with HIV in the United States on Alternatives to Oral Daily Antiretroviral Therapy.剂量反应：美国艾滋病毒感染者对口服每日抗逆转录病毒疗法替代品的看法。
AIDS Res Hum Retroviruses. 2020 Apr;36(4):324-348. doi: 10.1089/AID.2019.0175. Epub 2019 Dec 4.
本文引用的文献
1
Single tablet HIV regimens facilitate virologic suppression and retention in care among treatment naïve patients.单片剂抗HIV治疗方案有助于初治患者实现病毒学抑制并坚持治疗。
AIDS Care. 2018 Aug;30(8):1017-1024. doi: 10.1080/09540121.2018.1442554. Epub 2018 Feb 25.
2
Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy.用于HIV抗逆转录病毒疗法的口服每周一次给药系统的研发。
Nat Commun. 2018 Jan 9;9(1):2. doi: 10.1038/s41467-017-02294-6.
3
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.长效肌内注射卡替拉韦和利匹韦林治疗成人 HIV-1 感染（LATTE-2）：一项随机、开放标签、2b 期、非劣效性试验的 96 周结果。
Lancet. 2017 Sep 23;390(10101):1499-1510. doi: 10.1016/S0140-6736(17)31917-7. Epub 2017 Jul 24.
4
Implementation challenges for long-acting antivirals as treatment.长效抗病毒药物作为治疗手段的实施挑战。
Curr Opin HIV AIDS. 2015 Jul;10(4):282-9. doi: 10.1097/COH.0000000000000158.
5
Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis.用于HIV预防的长效替诺福韦艾拉酚胺（GS-7340）皮下植入剂的药代动力学
Antimicrob Agents Chemother. 2015 Jul;59(7):3913-9. doi: 10.1128/AAC.00656-15. Epub 2015 Apr 20.
6
Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials.降低HIV感染的药丸负担及每日一次抗逆转录病毒治疗方案：随机对照试验的荟萃分析
Clin Infect Dis. 2014 May;58(9):1297-307. doi: 10.1093/cid/ciu046. Epub 2014 Jan 22.
7
Increase in single-tablet regimen use and associated improvements in adherence-related outcomes in HIV-infected women.单一片剂方案使用率的增加以及与艾滋病病毒感染女性相关的与依从性相关结局的改善。
J Acquir Immune Defic Syndr. 2014 Apr 15;65(5):587-96. doi: 10.1097/QAI.0000000000000082.
8
Prevention of HIV-1 infection with early antiretroviral therapy.早期抗逆转录病毒疗法预防 HIV-1 感染。
N Engl J Med. 2011 Aug 11;365(6):493-505. doi: 10.1056/NEJMoa1105243. Epub 2011 Jul 18.
9
Trust in physicians and racial disparities in HIV care.医患信任和 HIV 护理中的种族差异。
AIDS Patient Care STDS. 2010 Jul;24(7):415-20. doi: 10.1089/apc.2009.0288.
10
Racial differences in attitudes toward innovative medical technology.对创新医疗技术态度上的种族差异。
J Gen Intern Med. 2006 Jun;21(6):559-63. doi: 10.1111/j.1525-1497.2006.00453.x.
Zotero 插件